Next Article in Journal
Stakeholders’ Perceptions of Factors Influencing the Use of Take-Home-Naloxone
Previous Article in Journal
Towards Medicines Reuse: A Narrative Review of the Different Therapeutic Classes and Dosage Forms of Medication Waste in Different Countries
Open AccessArticle

Accessing Mole-Scanning through Community Pharmacy: A Pilot Service in Collaboration with Dermatology Specialists

1
Boots UK, Thane Road, Nottingham NG90 1BS, UK
2
ScreenCancer UK Ltd., Innovation Centre, Maidstone Road, Chatham, Kent ME5 9FD, UK
3
School of Pharmacy, University of Nottingham, University Park, Nottingham NG7 2RD, UK
4
School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
*
Author to whom correspondence should be addressed.
Pharmacy 2020, 8(4), 231; https://doi.org/10.3390/pharmacy8040231
Received: 28 October 2020 / Revised: 20 November 2020 / Accepted: 27 November 2020 / Published: 3 December 2020
Early identification and treatment of malignant melanoma is crucial to prevent mortality. The aim of this work was to describe the uptake, profile of users and service outcomes of a mole scanning service in the community pharmacy setting in the UK. In addition, health care costs saved from the perspective of general practice were estimated. The service allowed patients to have concerning skin lesions scanned with a dermatoscopy device which were analyzed remotely by clinical dermatology specialists in order to provide recommendations for the patient. Patients were followed up to ascertain the clinical outcome. Data were analyzed for 6355 patients and 9881 scans across 50 community pharmacies. The majority of the scans required no further follow-up (n = 8763, 88.7%). Diagnosis was confirmed for 70.4% (n = 757/1118) of scans where patients were recommended to seek further medical attention. Of these, 44.3% were ultimately defined as normal (n = 335) and 6.2% as malignant melanoma (n = 47/757). An estimated 0.7% of scans taken as part of the service led to a confirmed diagnosis of malignant melanoma. This service evaluation has shown that a mole scanning service available within community pharmacies is effective at triaging patients and ultimately playing a part in identifying diagnoses of malignant melanoma. View Full-Text
Keywords: mole; pharmacy; melanoma; scanning; dermatoscopy mole; pharmacy; melanoma; scanning; dermatoscopy
Show Figures

Figure 1

MDPI and ACS Style

Kirkdale, C.L.; Archer, Z.; Thornley, T.; Wright, D.; Valeur, M.; Gourlay, N.; Ayerst, K. Accessing Mole-Scanning through Community Pharmacy: A Pilot Service in Collaboration with Dermatology Specialists. Pharmacy 2020, 8, 231. https://doi.org/10.3390/pharmacy8040231

AMA Style

Kirkdale CL, Archer Z, Thornley T, Wright D, Valeur M, Gourlay N, Ayerst K. Accessing Mole-Scanning through Community Pharmacy: A Pilot Service in Collaboration with Dermatology Specialists. Pharmacy. 2020; 8(4):231. https://doi.org/10.3390/pharmacy8040231

Chicago/Turabian Style

Kirkdale, Charlotte L.; Archer, Zoe; Thornley, Tracey; Wright, David; Valeur, Mette; Gourlay, Nicola; Ayerst, Kurt. 2020. "Accessing Mole-Scanning through Community Pharmacy: A Pilot Service in Collaboration with Dermatology Specialists" Pharmacy 8, no. 4: 231. https://doi.org/10.3390/pharmacy8040231

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop